Share this article:
Chantix is taking a real beating this month. First the FDA issues a warning based on cases of irritability, anxiety and even suicidal thinking that have been linked to Chantix use. Since patients with mental disorders were not studied before the drug was approved, there is concern about how patients with psychiatric problems will react to the drug. There is also the matter of a range of other side effects from seizures to accidents to drowsiness. The FAA recently said that pilots and air traffic controllers shouldn't take Chantix.

More than 6 million people have been prescribed Chantix, but all these reported side effects have led to a drastic decline of Chantix prescriptions by more than 50%. This is particularly concerning when you consider that the reports of side effects are based on isolated cases and no studies, smoking is a massive killer and Chantix is an effective treatment which works in over a third of patients.

When a person stops smoking, the body's levels of carbon monoxide decrease dramatically, smell and taste improve, and coughing lessens. The risk of pancreatic and esophageal cancer decreases almost immediately. A year after quitting, the risk of heart disease is cut in half. Quitting for 10 years cuts the risk of lung cancer in half.

Since smoking 25 cigarettes per day has been studied and found to be associated with three times greater death rates than normal, it is worth comparing this statistic with what the actual risk of Chantix is.

I do not take reported side effects lightly. But they must be studied. In the meantime, I am still willing to prescribe Chantix. I am much more concerned about the growing irrational fear against an effective treatment for a massive killer (cigarettes), than I am fearful of the drug itself.

Marc Siegel, MD, is an internist and associate professor of medicine at New York University and the author of False Alarm: The Truth About the Epidemic of Fear
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?